Patents Assigned to Hepacore Ltd.
  • Publication number: 20130084278
    Abstract: The present invention provides water-soluble reactive esters of carboxy polysaccharides and derivatives thereof. The reactive carboxy polysaccharide derivatives are useful per se in aqueous solutions or specifically for the formation of water-soluble covalent fibrinogen conjugates. A preferred conjugate is a hyaluronic acid-fibrinogen conjugate and fibrin adhesive, clot or matrix derived from it. Methods of preparation and methods of use in tissue repair and regeneration are also disclosed.
    Type: Application
    Filed: November 26, 2012
    Publication date: April 4, 2013
    Applicant: Hepacore Ltd.
    Inventor: Hepacore Ltd.
  • Patent number: 8329870
    Abstract: The present invention provides water-soluble reactive esters of carboxy polysaccharides and derivatives thereof. The reactive carboxy polysaccharide derivatives are useful per se in aqueous solutions or specifically for the formation of water-soluble covalent fibrinogen conjugates. A preferred conjugate is a hyaluronic acid-fibrinogen conjugate and fibrin adhesive, clot or matrix derived from it. Methods of preparation and methods of use in tissue repair and regeneration are also disclosed.
    Type: Grant
    Filed: January 6, 2008
    Date of Patent: December 11, 2012
    Assignee: Hepacore Ltd.
    Inventors: Boaz Amit, Hilla Barkay-Olami, Avner Yayon
  • Patent number: 8298528
    Abstract: The present invention relates in general to orthopedics and to a method for promoting repair of large bone defects, in particular non-union or delayed union fractures. Specifically the invention concerns the use of endothelial progenitor cell preparations for bone repair.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: October 30, 2012
    Assignee: Hepacore Ltd.
    Inventors: Avner Yayon, Dina Lewinson, Nimrod Rozen
  • Patent number: 7887831
    Abstract: A bone-enhancing composite material comprising synthetic apatite and at least one supplementary bioactive agent selected from a biocompatible polymer and an anti-resorptive agent added ab initio, methods of preparing said composite and uses thereof are provided. The physical and biological properties of the composite are controlled by the addition of specific supplementary bioactive agents as well as optional therapeutic agents. The composite may be used as a powder, a paste or an implant.
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: February 15, 2011
    Assignee: Hepacore Ltd.
    Inventor: Avner Yayon